The Global Systemic Lupus Erythematosus Treatment Market is valued approximately at USD 2.95 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 8.64% over the forecast ...

Immune cells called monocytes produce a key inflammatory protein called interleukin-1 beta (IL-1β) through an unconventional ...

With longer-term treatment, other side effects of glucocorticoids ... evidence Prevent damage Minimize both damage due to systemic lupus erythematosus and as consequence of medications ...

SLE: Systemic lupus erythematosus. Symptoms of systemic lupus ... Damage resulting from the disease and its treatment must be minimized. Long-term morbidity and mortality must be avoided.

Cambridge, Massachusetts Thursday, October 17, 2024, 17:00 Hrs [IST] ...

Cullinan Therapeutics said the U.S. Food and Drug Administration approved its investigation new drug application for CLN-978, a potential treatment for lupus. The biopharmaceutical company said the ...

Clinical stage biopharma Kezar Life Sciences is discontinuing its lupus nephritis (LN) clinical programme following the death ...

Immune cells called monocytes produce a key inflammatory protein called interleukin-1 beta (IL-1β) through an unconventional pathway in patients with ...

Analyst Julian Harrison of BTIG maintained a Buy rating on Cullinan Management (CGEM – Research Report), retaining the price target of ...

Number 5: The FDA has approved Imuldosa (ustekinumab-srlf), a biosimilar referencing Stelara (ustekinumab), for the treatment ...